MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In


News Categories




Company Resumes Marketing of Iclusig (Ponatinib) for Leukemia Patients

FDA okays revised prescribing information (December 21)

The FDA has approved revised U.S. prescribing information (USPI) and a Risk Evaluation and Mitigation Strategy (REMS) for Iclusig (ponatinib, Ariad Pharmaceuticals) that allows immediate resumption of the drug’s marketing and commercial distribution. The USPI includes a revised indication statement and boxed warning, updated safety information, and recommendations regarding dosing considerations for prescribers.

Iclusig (pomatinib) is indicated for the treatment of adult patients with:

  • T315I-positive chronic myeloid leukemia (CML) (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)
  • Chronic phase, accelerated phase, or blast phase CML or Ph+ ALL for whom no other tyrosine-kinase inhibitor therapy is indicated

The boxed warning for Iclusig has been revised to alert health care professionals and patients to the risk of vascular occlusive events and includes a new warning for heart failure. The starting dose of Iclusig remains 45 mg daily.

Ponatinib is a tyrosine kinase inhibitor (TKI). The drug’s primary target is BCR-ABL, an abnormal tyrosine kinase that is expressed in CML and Ph+ ALL. Ponatinib was designed to inhibit the activity of BCR-ABL. The drug targets not only native BCR-ABL but also its isoforms, which carry mutations that confer resistance to treatment, including the T315I mutation, a common mutation that has been associated with resistance to other approved TKIs.

Source: Ariad Pharmaceuticals; December 21, 2013.

More stories